Rising incidence of small renal masses: a need to reassess treatment effect - PubMed (original) (raw)
. 2006 Sep 20;98(18):1331-4.
doi: 10.1093/jnci/djj362.
Affiliations
- PMID: 16985252
- DOI: 10.1093/jnci/djj362
Rising incidence of small renal masses: a need to reassess treatment effect
John M Hollingsworth et al. J Natl Cancer Inst. 2006.
Abstract
The incidence of kidney cancer has been rising over the last two decades, especially in cases where the disease is localized. Although rates of renal surgery parallel this trend, mortality rates have continued to rise. To investigate the basis of this "treatment disconnect" (i.e., increased rates of treatment accompanied by increased mortality rates), we analyzed patient data from nine registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. We assembled a cohort of 34,503 kidney cancer patients and derived incidence, treatment, and mortality trends for kidney cancer, overall and as a function of tumor size. From 1983 to 2002, the overall age-adjusted incidence rate for kidney cancer rose from 7.1 to 10.8 cases per 100,000 US population; tumors < or = 4 cm in size accounted for most of the increase. Adjusted rates of renal surgery increased concurrently, most notably for tumors < or = 4 cm (0.9-3.6 surgeries per 100,000 US population). However, among kidney cancer patients, all-cause mortality per 100,000 US population increased from 1.5 deaths in 1983 to 6.5 deaths in 2002, with the greatest absolute increase noted for patients with lesions > 7 cm. Our results demonstrate that the rising incidence of kidney cancer is largely attributable to an increase in small renal masses that are presumably curable. The fact that increased detection and treatment of small tumors is not reducing mortality argues for a reassessment of the current treatment paradigm.
Comment in
- Re: Rising incidence of small renal masses: a need to reassess treatment effect.
Chow WH, Linehan WM, Devesa SS. Chow WH, et al. J Natl Cancer Inst. 2007 Apr 4;99(7):569-70; author reply 570-1. doi: 10.1093/jnci/djk114. J Natl Cancer Inst. 2007. PMID: 17406001 No abstract available.
Similar articles
- Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis.
Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Hollingsworth JM, et al. Cancer. 2007 May 1;109(9):1763-8. doi: 10.1002/cncr.22600. Cancer. 2007. PMID: 17351954 - A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses.
Zini L, Perrotte P, Jeldres C, Capitanio U, Duclos A, Jolivet-Tremblay M, Arjane P, Péloquin F, Pharand D, Villers A, Montorsi F, Patard JJ, Karakiewicz PI. Zini L, et al. BJU Int. 2009 Apr;103(7):899-904; discussion 904. doi: 10.1111/j.1464-410X.2008.08247.x. Epub 2009 Jan 20. BJU Int. 2009. PMID: 19154499 - Epidemiology, clinical staging, and presentation of renal cell carcinoma.
Decastro GJ, McKiernan JM. Decastro GJ, et al. Urol Clin North Am. 2008 Nov;35(4):581-92; vi. doi: 10.1016/j.ucl.2008.07.005. Urol Clin North Am. 2008. PMID: 18992612 Review. - Kidney cancer: the new landscape.
Linehan JA, Nguyen MM. Linehan JA, et al. Curr Opin Urol. 2009 Mar;19(2):133-7. doi: 10.1097/MOU.0b013e328323f5ab. Curr Opin Urol. 2009. PMID: 19188766 Review.
Cited by
- The first competing risk survival nomogram in patients with papillary renal cell carcinoma.
Su X, Hou NN, Yang LJ, Li PX, Yang XJ, Hou GD, Gao XL, Ma SJ, Guo F, Zhang R, Zhang WH, Qin WJ, Wang FL. Su X, et al. Sci Rep. 2021 Jun 4;11(1):11835. doi: 10.1038/s41598-021-91217-z. Sci Rep. 2021. PMID: 34088935 Free PMC article. - Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer.
Smaldone MC, Chen DY, Yu JQ, Plimack ER. Smaldone MC, et al. Biologics. 2012;6:395-407. doi: 10.2147/BTT.S30413. Epub 2012 Nov 19. Biologics. 2012. PMID: 23204838 Free PMC article. - Ultrasound-guided posterior quadratus lumborum block can reduce postoperative opioid consumption and promote rapid recovery in patients undergoing sutureless laparoscopic partial nephrectomy: A triple-blind, randomized, controlled study.
Zhu Y, Li Z, Qin S, Xu H, He J, Sheng F, Zhao Q, Kang Y, Gao X, Li S, Chai J, Chen L, Wang W. Zhu Y, et al. Front Oncol. 2022 Oct 6;12:969452. doi: 10.3389/fonc.2022.969452. eCollection 2022. Front Oncol. 2022. PMID: 36276114 Free PMC article. - Is there enough evidence supporting the clinical adoption of clear cell likelihood score (ccLS)? An updated systematic review and meta-analysis.
Zhong J, Hu Y, Xing Y, Liu X, Ge X, Wang Y, Shi Y, Lu J, Yang J, Song Y, Lu M, Chu J, Zhang H, Ding D, Yao W. Zhong J, et al. Insights Imaging. 2024 Oct 9;15(1):242. doi: 10.1186/s13244-024-01829-y. Insights Imaging. 2024. PMID: 39382764 Free PMC article. - Clinical Profile and Outcome of Patients Operated on for Renal Cell Carcinoma: Experience from a Tertiary Care Center in a Developing Country.
Adem RY, Hassen SM, Abdulaziz M, Ahmed AI, Jemberie AM, Gebeyehu YT, Sedeta AM, Gebrehiwot FG, Abebe E, Berhe T. Adem RY, et al. Res Rep Urol. 2022 Nov 10;14:389-397. doi: 10.2147/RRU.S376720. eCollection 2022. Res Rep Urol. 2022. PMID: 36394071 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical